To: | Regeneron Pharmaceuticals, Inc. (trademark@ogrp.com) |
Subject: | TRADEMARK APPLICATION NO. 90124699 - QOVENVID - 554.1748UST1 |
Sent: | 9/1/2020 1:02:26 PM |
Sent As: | ECOMPET |
Attachments: |
United States Patent and Trademark Office (USPTO)
U.S. Application Serial No. 90124699
U.S. Registration No.
Mark: QOVENVID
|
|
Correspondence Address: Terrence J. McAllister OHLANDT, GREELEY, RUGGIERO & PERLE, LLP 10TH FLOOR ONE LANDMARK SQUARE STAMFORD CT 06901 |
|
Owner: Regeneron Pharmaceuticals, Inc.
|
|
Reference/Docket No. 554.1748UST1
Correspondence Email Address: trademark@ogrp.com |
|
PETITION TO DIRECTOR GRANTED
Issue date: September 1, 2020
Regeneron Pharmaceuticals, Inc. (petitioner) has petitioned the Director of the United States Patent and Trademark Office (USPTO) to exercise supervisory authority to prioritize initial examination of the above identified application. The Director has authority to review the request. 37 C.F.R. §2.146(a)(3). The petition is granted.
FACTS
On August 19, 2020, petitioner submitted the above identified application for registration of the mark QOVENVID used in connection with “Pharmaceutical preparations for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders; antivirals for treatment or prevention of COVID-19, coronavirus disease, and respiratory diseases and disorders” in International Class 05. Petitioner submitted this petition requesting to prioritize initial examination of the application because the identified goods are intended to prevent or treat COVID-19. The petition also included the section of the Code of Federal Regulations (CFR) under which the goods are regulated by the United States Food and Drug Administration (FDA).
DISCUSSION
The Director may exercise supervisory authority on petition in appropriate circumstances. 35 U.S.C. §2; 37 C.F.R. §2.146(a)(3); TMEP §1707. Petitioner’s verified statements that the goods identified in the subject application are intended to prevent or treat COVID-19 support the invocation of supervisory authority in this case. See June 12, 2020 Notice titled “Relief Available to Trademark and Service Mark Applicants in View of the COVID-19 Outbreak: Petitions to Prioritize the Initial Examination of Certain Applications”; TMEP §1710. In addition, petitioner provided evidence that the goods are regulated by the United States Food and Drug Administration (FDA) under 21 C.F.R. §312.
Accordingly, the Director will exercise supervisory authority to prioritize initial examination of the above identified application.
DECISION
The petition is granted. The above identified application will be immediately assigned to an examining attorney.[1]
/Seth Dennis/
Attorney Advisor
Office of the Deputy Commissioner
for Trademark Examination Policy
(571) 272-9495
seth.dennis@uspto.gov
[1] Petitioner may further expedite the examination review process by responding promptly to any Office action, phone call, or email from the examining attorney. However, following examination, all approved trademark applications are published for opposition in the Trademark Official Gazette. Following publication, there is a 30-day period during which the public may file oppositions or extensions of time to oppose. 37 C.F.R. §§2.101(c), 2.102(a)(1).